CANY
CTMX icon

Caxton Associates (New York)’s CytomX Therapeutics CTMX Stock Holding History

Caxton Associates (New York)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,143
Closed -$93K – 491
2020
Q1 		$93K Buy
+12,143
New +$84.7K 0.02% 390

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Caxton Associates (New York)'s CTMX Position: Q2 2020 in Review

Caxton Associates (New York) sold out of CytomX Therapeutics (CTMX) in Q2 2020, closing a stake of 12,143 shares — an estimated $93K sold.

Caxton Associates (New York) first reported a position in CTMX in Q1 2020 and held it in 1 quarter. The position peaked at $93K in Q1 2020. 134 funds tracked by Wall St. Rank hold CTMX as of Q2 2020.

  • Caxton Associates (New York) reported no remaining CytomX Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 12,143 CytomX Therapeutics shares in Q2 2020, an estimated $93K.
  • Caxton Associates (New York) first reported a position in CytomX Therapeutics in Q1 2020 and held it in 1 quarter.
  • Caxton Associates (New York)'s CytomX Therapeutics position peaked at $93K in Q1 2020.
  • 134 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2020.

Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.